Amgen Inc

Most Recent

  • uploads///Pharma
    Earnings Report

    Johnson & Johnson’s Pharmaceuticals Segment Grows in 2Q15

    Johnson & Johnson’s (JNJ) Pharmaceuticals segment grew by 1.0% at constant exchange rates, reporting a revenue of $7,946 million for 2Q15 over 2Q14.

    By Mike Benson
  • uploads///revenue EE
    Earnings Report

    How Vertex’s Revenue and Earnings Surprised in 2Q16

    Vertex Pharmaceuticals (VRTX) reported its 2Q16 earnings on July 27, 2016. VRTX surpassed Wall Street analysts’ projections and reported revenue of $431.6 million.

    By Jillian Dabney
  • uploads///Cosentyx
    Company & Industry Overviews

    How Is Novartis’s Cosentyx Positioned after 4Q17?

    In 4Q17, Novartis’s (NVS) Cosentyx generated revenues of $615 million compared to $391 million in 4Q16, which reflected ~57% growth on a year-over-year (or YoY) basis and ~11% growth quarter-over-quarter.

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    Restricted Access Continues to Impact Praluent Sales in 2016

    Praluent is one of the Regeneron’s key new additions in the cardiovascular segment. It’s a PCSK9 therapy approved for lowering LDL cholesterol in patients.

    By Margaret Patrick
  • uploads///Relative valuation
    Earnings Report

    Regeneron Continues to Trade at Premium

    Regeneron is consistently trading at a premium compared to its peers. As of January 22, it was trading at a valuation multiple of 26.67x its earnings.

    By Jillian Dabney
  • uploads///Chart
    Company & Industry Overviews

    What Did AGN’s US Medical Aesthetics Segment Contribute in 1Q16?

    Allergan’s US medical aesthetics segment includes facial aesthetics, medical dermatology products, and a wide range of silicone and saline breast implants.

    By Mike Benson
  • uploads///Graph
    Earnings Report

    Amgen Continues to Control Operating Expenses in 3Q15

    In 3Q15, Amgen recorded total operating expenses of ~$3.4 billion. This fall in expenses enabled the company to report a net profit margin of ~36.4%.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Alexion Pharmaceuticals Adds Metabolic Drug Kanuma to Portfolio

    Kanuma was acquired by Alexion Pharmaceuticals on completion of the acquisition of Synageva Pharmaceuticals in June 2015.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Must-Read: Amgen’s 3Q15 Earnings and Conference Call

    In its 3Q15 earnings report released on October 28, Amgen reported YoY revenue growth of ~14.0%, from $5.0 billion in 3Q14 to $5.7 billion in 3Q15.

    By Margaret Patrick
  • uploads///BGNE
    Company & Industry Overviews

    Do Analysts See Any Upside in BeiGene Stock?

    Of the 11 analysts covering BeiGene (BGNE), four have given it “strong buys,” and seven have given it “buys.”

    By Kenneth Smith
  • uploads///Graph
    Earnings Report

    Analysts Expect Biogen’s Net Profit Margins to Rise in 3Q15

    Biogen’s (BIIB) 3Q15 earnings results will be announced on October 21, 2015. Analysts expect that the company will report lower net profit margins as compared to 2Q15.

    By Margaret Patrick
  • uploads///acquisition
    Company & Industry Overviews

    Medivation Is for Sale: How Much Should It Get?

    Considering the prospects for the pipeline, Medivation should get more than what Sanofi offered. It will probably get more than what Pharmacyclics received.

    By Jillian Dabney
  • uploads///US Investment Grade Bond Fund Flows
    Company & Industry Overviews

    Inflows into Investment-Grade Bond Funds Increase Last Week

    Investment-grade bond (AGG) funds saw net inflows of $1.53 billion in the week ending May 1, 2015.

    By David Ashworth
  • uploads///Graph
    Company & Industry Overviews

    Behind Amgen’s Plans to Penetrate the Migraine Segment

    Amgen and Novartis are exploring an investigational drug that is a CGRP antibody, AMG 334, for the treatment of episodic and chronic migraine headaches.

    By Margaret Patrick
  • Financials

    Must-know 3Q updates from Dan Loeb’s Third Point Partners

    In this series Activist investor Dan Loeb’s fund, Third Point Partners LP, disclosed some of the positions traded during 3Q14 in its 3Q investor letter. In this series, we’ll go through the details of these positions and Third Point’s rationale for adding or exiting its stakes. In its 3Q letter, the fund said it “continued […]

    By Samantha Nielson
  • Healthcare

    Third Point Partners ups stake in Amgen

    The fund noted in its letter that “Amgen has all the hallmarks of a hidden value situation, which is one of the fund’s favorite investment themes.”

    By Samantha Nielson
  • uploads///Graph
    Earnings Report

    Amgen’s Nephrology Drugs Expect Falling Revenue in 4Q15

    Analysts projected a fall in the revenue for Amgen’s nephrology drugs, Aranesp and Epogen, in 4Q15. The drugs are expected to suffer in the coming quarters.

    By Margaret Patrick
  • uploads///Graph Part  Nov
    Company & Industry Overviews

    Amgen Rises by 2% as XBI’s Large-Cap Stocks Rally

    Amgen closed at $157.60 and was trading above its 50- and 100-day moving averages. The stock also witnessed a rise in trading volumes.

    By Peter Neil
  • uploads///Graph
    Company & Industry Overviews

    Amgen: Exploring Opportunities in the Bone Segment

    Amgen’s Prolia is the leading brand for treating postmenopausal osteoporosis, or PMO, in women with a high risk of bone fracture.

    By Margaret Patrick
  • uploads///Neuroscience
    Earnings Report

    Bristol-Myers Squibb’s Neuroscience and Immunoscience Segments

    Sales for Bristol-Myers Squibb’s (BMY) neuroscience segment declined over 80% in 2Q15, while the immunoscience segment’s sales improved ~15% in 2Q15 as compared to 2Q14.

    By Mike Benson
  • uploads///syringe _
    Company & Industry Overviews

    Teva’s Granix Gets FDA Approval for Expanded Indication

    Today, Teva Pharmaceutical Industries (TEVA) announced that its Granix (tbo-filgrastim) injection has received FDA approval for a new presentation and indication.

    By Sarah Collins
  • uploads///Part  Graph
    Company & Industry Overviews

    Regeneron’s Stock Reacts to Dupilumab Phase 3 Trials

    Regeneron Pharmaceuticals (REGN) rose 9.3% during the week ending April 1, 2016.

    By Peter Neil
  • uploads///Kisqali BTD
    Company & Industry Overviews

    Novartis Receives 2 Breakthrough Therapy Designations in January

    In January 2018, the FDA granted a BTD to Novartis’s (NVS) Promacta for use along with standard immunosuppressive therapy.

    By Daniel Collins
  • uploads///sales estimates
    Company & Industry Overviews

    Competition Dynamics for Ajovy—Teva’s Migraine Drug

    Approved by the FDA on September 14, Teva’s Ajovy has multiple competitors set to enter the market.

    By Sarah Collins
  • uploads///Revlimid revenue
    Company & Industry Overviews

    Revlimid Could Continue to Drive Celgene’s Revenue Growth in 2017

    In 2016, Celgene’s (CELG) Revlimid generated revenues of around $6.9 billion, which reflected a ~20% year-over-year (or YOY) growth.

    By Daniel Collins
  • uploads///Graph
    Earnings Report

    Biogen Trades at High Valuation Multiples Due to Strong Research Pipeline

    After the release of its 3Q15 earnings results on October 21, Biogen was trading at PE multiples in the range of 13.8x–15.3x.

    By Margaret Patrick
  • uploads///Humira Revenues
    Company & Industry Overviews

    Humira May Continue to Drive AbbVie’s Revenue Growth

    In 2016, AbbVie’s (ABBV) drug Humira reported revenue of ~$16.0 billion, which reflected a ~15% year-over-year (or YoY) rise.

    By Daniel Collins
  • uploads///becdaabdacaceddd
    Earnings Report

    Johnson & Johnson Stock Remained Neutral to 2Q15 Earnings

    Due to the decelerating revenue growth over all segments, Johnson & Johnson (JNJ) reported a decrease in its top line by ~8.8% in its 2Q15 earnings release on July 14, 2015.

    By Mike Benson
  • uploads///Chart  Other
    Earnings Report

    A Look at Bristol-Myers Squibb’s Other Segments in 1Q17

    Bristol-Myers Squibb’s (BMY) other segments include the Neuroscience segment, the Cardiovascular segment, and the Immuno-Science segment.

    By Mike Benson
  • uploads///Graph
    Earnings Report

    Factors That Will Determine Repatha’s Future Commercial Success

    Amgen (AMGN) believes that Repatha will be widely accepted as a major cardiovascular therapy for high-risk patients.

    By Margaret Patrick
  • uploads///pill _
    Earnings Report

    What Analysts Recommend for Mylan before Q2 2018 Earnings

    Mylan (MYL) plans to release its Q2 results on August 8. Thirteen of the 20 analysts covering the stock have given it a “buy” or “strong buy.”

    By Sarah Collins
  • uploads///pipeline
    Company & Industry Overviews

    Pfizer Has Strong Track Record since 2010

    As of November 1, Pfizer had ~94 projects in various development stages. More than 40% of these projects are in phase three or the registration phase.

    By Jillian Dabney
  • uploads///Graph
    Company & Industry Overviews

    Opdivo Is a Key Growth Driver for Bristol-Myers Squibb in 2016

    On November 10, 2016, the FDA approved Opdivo as a treatment option for patients suffering with recurring or metastatic squamous cell carcinoma of the head and neck (or SCCHN).

    By Margaret Patrick
  • uploads///Part
    Company & Industry Overviews

    Wall Street Looks at Sales Forecasts for Mylan’s Fulphila

    According to Leerink analyst Amy Fadia, Fulphila is expected to generate sales of $73.0 million in 2018. Fadia expects Fulphila’s sales to reach $260.0 million in 2019.

    By Sarah Collins
  • uploads///Graph
    Earnings Report

    Behind Celgene’s Blockbuster Revenue Hit in 4Q16

    In 2016, Celgene’s (CELG) Otezla attained blockbuster status by earning revenues in excess of $1 billion as a therapy for psoriasis and psoriatic arthritis.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Entering Migraine Market Won’t Be Easy for Novartis, Amgen

    Novartis (NVS) and Amgen (AMGN) recently announced that the CGRP inhibitor therapy, AMG 334, reported positive results in a Phase 2 clinical trial as a therapy for preventing chronic migraine.

    By Margaret Patrick
  • uploads///Chart  Rev EPS
    Company & Industry Overviews

    What’s Gilead Sciences’ Valuation?

    Gilead’s stock price has risen ~8.9% in the last 12 months. Wall Street analysts estimate that the stock price will fall ~4.5% over the next 12 months.

    By Mike Benson
  • uploads///Alliance in companeis based in US Japan
    Company & Industry Overviews

    Multinational and Japanese Pharmaceuticals Should Build Alliances

    The Japanese pharmaceuticals market is not very welcoming to foreign companies. Similarly, the Japanese population is quite loyal to domestic manufacturers.

    By Jillian Dabney
  • uploads///Kanuma
    Earnings Report

    How Kanuma’s Addition to Alexion’s Portfolio Impacts Its Earnings

    Alexion added Kanuma to its portfolio in 2015 after its Synageva acquisition. But ALXN didn’t have much time to build diagnostics as it did with Strensiq.

    By Jillian Dabney
  • uploads///RD expenses Part
    Earnings Report

    How Much Does Biogen Spend on Research and Development?

    Biogen’s (BIIB) R&D expenses for 4Q15 were $542 million, or 19% of its total revenue, including a $60 million payment to Mitsubishi Tanabe.

    By Peter Neil
  • uploads///patents
    Company & Industry Overviews

    Why Is Enbrel So Important for Amgen?

    YTD, Amgen’s (AMGN) stock has already fallen 9%. Perhaps the pressure that Enbrel (etanercept) is seeing is to blame for the negative investor sentiment.

    By Jillian Dabney
  • uploads///Immunology Oncology
    Company & Industry Overviews

    A Look into Merck’s Immunology and Oncology Portfolio

    In 1H17, Remicade generated revenues of around $437 million, which is a 37% decline year-over-year.

    By Daniel Collins
  • uploads///Nephrology
    Company & Industry Overviews

    How Amgen’s Nephrology Drugs Are Positioned after 2Q17?

    In 2Q17, Amgen’s (AMGN) Aranesp generated revenues of ~$535 million, which represented a 6% year-over-year rise.

    By Daniel Collins
  • uploads///Oncology Franchise
    Company & Industry Overviews

    The Latest on TEVA’s Oncology Business

    In 1H17, Teva Pharmaceutical’s (TEVA) oncology business generated revenues of ~$550 million, or ~9% lower YoY (year-over-year).

    By Daniel Collins
  • uploads///pills _
    Company & Industry Overviews

    Teva Announces First-to-File Launch of Generic Cialis

    Yesterday, Teva Pharmaceutical Industries (TEVA) announced the exclusive FTF (first-to-file) launch of the generic Cialis1 tablets in the US.

    By Sarah Collins
  • uploads///Graph
    Company & Industry Overviews

    Gilead Sciences’ Valuation Continues to Lag behind Peers

    Post 2014, Gilead Sciences has traded at lower valuation multiples, as investors are uncertain of the company’s ability to continue its leadership in the global HIV market.

    By Margaret Patrick
  • uploads///Chart
    Earnings Report

    Why Eli Lilly Expects 2Q17 Revenue Growth

    As per analysts’ estimates, Eli Lilly’s (LLY) revenues could rise ~3.6% to $5.6 billion in 2Q17.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    What Do Analysts Recommend for AbbVie?

    Analysts updated their recommendations for AbbVie (ABBV) after the release of its 1Q16 earnings on April 28, 2016.

    By Margaret Patrick
  • uploads///ANR
    Company & Industry Overviews

    Why Are Most Analysts Recommending a ‘Buy’ for Vertex?

    On February 16, 2016, after Vertex’s (VRTX) 4Q15 and fiscal 2015 earnings release, revised ratings showed that 76% of analysts now recommend a “buy” for Vertex stock.

    By Jillian Dabney
  • uploads///Humira revenues
    Company & Industry Overviews

    AbbVie’s Humira Continues to Generate High Revenues

    In 2Q17, AbbVie’s (ABBV) Humira generated revenues of $4.7 billion, which was a 14.0% rise YoY (year-over-year) and a 15.0% rise QoQ (quarter-over-quarter).

    By Daniel Collins
  • uploads///Merck Performance
    Company & Industry Overviews

    How Merck Is Expected to Perform in 2017

    In 1Q17, Merck (MRK) generated revenues of ~$9.4 billion, which reflected 1% YoY growth. Merck expects its GAAP net revenues in fiscal 2017 to reach $39.1 billion–$40.3 billion.

    By Daniel Collins
  • uploads///GUIDANCE
    Company & Industry Overviews

    How’s Gilead Sciences Expected to Perform in 2016?

    Gilead Sciences lowered its guidance for fiscal 2016 due to weak 2Q16 results reported on July 25. It expects its 2016 revenues to be $29.5 billion–$30.5 billion.

    By Sarah Collins
  • uploads///Graph
    Earnings Report

    What Biogen Is Doing that Put It in Good Favor with Analysts

    Based on recommendations from 25 broker companies, a Bloomberg survey reported that 62.5% of analysts gave Biogen (BIIB) “buy” recommendations.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Which of Amgen’s Drugs Could Witness Muted Growth in 2016?

    Wall Street analysts have projected that Xgeva’s revenues will reach about $1.6 billion in 2016, which represents a YoY growth of about 12.3% for Amgen.

    By Margaret Patrick
  • uploads///Graph Part  Oct
    Company & Industry Overviews

    Baxalta in the XBI Top Ten Large Caps

    Baxalta (BXLT) rose by 6.2% for the week ending October 16, 2015. The stock rose as it received the Health Canada Approval for OBIZUR.

    By Peter Neil
  • uploads///Graph
    Earnings Report

    Gilead Sciences in 4Q15: Analysts Project Modest Revenue Growth

    On February 02, 2016, Gilead Sciences will announce its 4Q15 earnings for the period ending December 31, 2015. Analysts expect modest revenue growth.

    By Margaret Patrick
  • uploads///PE multiple
    Company & Industry Overviews

    Why Is Vertex Pharmaceuticals’ Valuation at a Discount?

    On February 17, 2016, Vertex Pharmaceuticals (VRTX) was trading at a forward PE multiple of 15.20x. It’s trading at a discount when compared to peers Alexion (ALXN) and Regeneron (REGN).

    By Jillian Dabney
  • uploads///Graph Part
    Company & Industry Overviews

    Incyte Was a Star Performer from August 10–17, 2015

    By market cap size, Incyte (INCY) is among the top ten holdings of the SPDR S&P Biotech ETF (XBI). Incyte has a weight of 1.22% in XBI’s portfolio.

    By Peter Neil
  • uploads///Graph
    Company & Industry Overviews

    Celgene Estimates Robust Revenue in 2017

    In 2017, Celgene (CELG) expects to earn revenues of $13.0 billion–$13.4 billion, which would be a YoY (year-over-year) growth of around 18.0%.

    By Margaret Patrick
  • uploads///ANR
    Earnings Report

    What Can Investors Expect from Regeneron’s 4Q15 Earnings?

    Regeneron will report its earnings for 4Q15 and fiscal 2015 on February 9, 2016. It will report the earnings before the financial markets open in the US.

    By Jillian Dabney
  • uploads///microscope _
    Earnings Report

    BeiGene’s Q2 2018 Earnings: Reports Revenue Growth

    BeiGene (BGNE) released its Q2 2018 earnings on August 9. BGNE surpassed analysts’ estimates for revenues but missed its EPS estimates.

    By Mike Benson
  • uploads///aerial view of various medical pills pharmaceutical
    Company & Industry Overviews

    An Easier Way to Understand the Pharma Industry

    In 2018, the global pharmaceutical industry stood at $1.2 trillion, and experts expect $1.5 trillion by 2023. Here’s everything investors need to know.

    By Sybil Prowse
  • Healthcare

    Amgen has attractive, high-growth assets

    The principal products represented 92% of Amgen’s worldwide product sales for the first half of 2014. Total product sales in 3Q14 rose 4% year-over-year, mainly driven by Kyprolis, Prolia, Neulasta, and Xgeva.

    By Samantha Nielson
  • Healthcare

    Third Point believes Amgen’s acquisitions should have done more

    Faced with expiring patents and increasing competition for its blockbuster drugs, Amgen acquired Onyx to benefit from the latter’s innovative oncology portfolio and pipeline.

    By Samantha Nielson
  • uploads///Analysts recommendation
    Company & Industry Overviews

    What Amgen’s Analysts Recommend in August 2017

    Of the 24 analysts covering Amgen, four have recommended a “strong buy” for the stock, while six have recommended a “buy.”

    By Daniel Collins
  • uploads///AdobeStock_
    Company & Industry Overviews

    Amgen and Celgene’s Otezla Deal: Key Highlights

    On August 26, Amgen (AMGN) announced the purchase of leading immunology drug Otezla from Celgene (CELG) for a cash consideration of $13.4 billion.

    By Margaret Patrick
  • uploads///Pfizer stock
    Company & Industry Overviews

    Why Pfizer Stock Continues to Tank after Mylan Deal

    Pfizer stock (PFE) has fallen 10% in the past two days on its deal with Mylan (MYL) and its lower earnings guidance.

    By Maitali Ramkumar
  • uploads///harlie raethel ouyjDk KdfY unsplash
    Company & Industry Overviews

    Bone Health and Cancer Treatments: Amgen’s Key Growth Areas

    Amgen’s (AMGN) leading bone health drug, Prolia, reported revenue of $592 million in the first quarter, a year-over-year rise of 20% driven by 17% volume growth.

    By Margaret Patrick
  • uploads///analysis background bacteria
    Company & Industry Overviews

    What Analysts Recommend for LLY and AMGN

    Eli Lilly and Company (LLY) is down 0.20%, and Amgen (AMGN) is down 3.88% in 2019 on a year-to-date basis. Investors seem disappointed with the first-quarter results of both companies.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    A Look at Cosentyx, Novartis’s Fast-Growing Immunology Drug

    In the first quarter, Novartis’s (NVS) Cosentyx reported net sales of $791 million, a YoY (year-over-year) rise of 41% on a constant currency basis.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Comparing Amgen’s and Merck’s Dividends and Tax Rates

    Amgen (AMGN) and Merck (MRK) reported dividends per share of $5.28 and $1.99, respectively, in fiscal 2018.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Amgen or Merck: Which Will See the Most Revenue Growth?

    In its fourth-quarter conference call, Amgen (AMGN) guided for fiscal 2019 revenue of $21.8 billion–$22.9 billion, driven by robust growth anticipated for recently launched Aimovig, Repatha, and biosimilars, and the company’s international marketing strategy.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    What Are Teva Pharmaceutical’s Key Growth Drivers in 2019?

    On its fourth-quarter earnings conference call, Teva Pharmaceutical (TEVA) highlighted Ajovy and Austedo as its key growth drivers for 2019.

    By Margaret Patrick
  • Moat Index: Dramatic Sector Allocation Shift in 2018
    Healthcare

    Moat Index: Dramatic Sector Allocation Shift in 2018

    The healthcare sector dominated the sector weighting for the Morningstar Wide Moat Index in 2018. The sector returned ~5% in 2018.

    By VanEck
  • uploads///TMO
    Company & Industry Overviews

    Do Analysts See Any Upside for Thermo Fisher Stock?

    Of the 17 analysts covering Thermo Fisher Scientific (TMO), 14 recommend ” buy” or a higher rating, and three recommend “hold.”

    By Kenneth Smith
  • uploads///cells _
    Company & Industry Overviews

    Taking Stock of BeiGene’s Latest Performance

    BeiGene is a company focused on bringing to market molecularly targeted and immuno-oncology drugs for the treatment of cancer.

    By Kenneth Smith
  • uploads///VRTX
    Company & Industry Overviews

    Do Analysts See Any Upside for Vertex Stock?

    Of the 25 analysts covering Vertex Pharmaceuticals (VRTX), 21 recommend “buy” or a higher rating, and four recommend “hold.”

    By Kenneth Smith
  • uploads///VRTX
    Company & Industry Overviews

    Vertex Pharmaceuticals’ Gross Margin Trends

    Kalydeco, Orkambi, and Symdeko are Vertex Pharmaceuticals’ (VRTX) products on the market.

    By Kenneth Smith
  • uploads///BLUE
    Company & Industry Overviews

    Do Analysts See Any Upside for bluebird bio Stock?

    In this year’s third quarter, bluebird bio (BLUE) generated net interest income of $4.59 million.

    By Kenneth Smith
  • uploads///BLUE
    Company & Industry Overviews

    Understanding bluebird bio’s Operational Performance

    In 2018 and 2019, bluebird bio (BLUE) is expected to generate revenues of $43.62 million and $67.0 million, respectively.

    By Kenneth Smith
  • uploads///dna _
    Company & Industry Overviews

    Taking Stock of bluebird bio’s Performance

    In the third quarter, bluebird bio’s total revenue rose YoY (year-over-year) to $11.53 million from $7.71 million.

    By Kenneth Smith
  • uploads///REGN
    Company & Industry Overviews

    Do Analysts See Any Upside for Regeneron Stock?

    Of the 26 analysts covering Regeneron Pharmaceuticals (REGN), eight recommend “buy” or a higher rating, 17 recommend “hold,” and one recommends “sell.”

    By Kenneth Smith
  • uploads///SGEN
    Company & Industry Overviews

    What Seattle Genetics’ Bottom-Line Trend Indicates

    In December 2018, of the total 13 analysts covering Seattle Genetics, eight analysts have given Seattle Genetics stock a “buy” or higher rating.

    By Kenneth Smith
  • uploads///dna _
    Company & Industry Overviews

    How’s Seattle Genetics Positioned?

    Seattle Genetics generated total revenues of $169.42 million in the third quarter of 2018 as compared with $135.29 million in the comparable period of 2017.

    By Kenneth Smith
  • uploads///REGN
    Company & Industry Overviews

    Regeneron Pharmaceuticals’ Gross Margin Trends

    In fiscal 2018 and fiscal 2019, Regeneron Pharmaceuticals (REGN) is expected to generate revenue of $6.49 billion and $7.16 billion, respectively, compared with revenue of $5.87 billion in fiscal 2017.

    By Kenneth Smith
  • uploads///Graph
    Company & Industry Overviews

    Ajovy Is a New Growth Driver for Teva Pharmaceutical

    On September 14, Teva Pharmaceutical (TEVA) issued a press release announcing FDA approval of humanized monoclonal antibody and anti-calcitonin gene-related peptide (or CGRP) therapy.

    By Margaret Patrick
  • uploads///molecule _
    Company & Industry Overviews

    Taking Stock of Sangamo’s Financial Performance

    In this series, we explore Sangamo’s financials, analysts’ views on the stock, and the company’s valuation metrics.

    By Kenneth Smith
  • uploads///thermometer _
    Company & Industry Overviews

    Pfizer Stock Has Risen ~20% in 2018

    Pfizer’s (PFE) stock price opened at $36.23 on January 2 and reached $43.51 on November 16, which represents ~20.0% growth YTD.

    By Daniel Collins
  • uploads///ALXN
    Company & Industry Overviews

    How Analysts View Alexion Stock

    In November 2018, of the total 18 analysts covering Alexion Pharmaceuticals (ALXN), 16 analysts have given the stock a “buy” or higher rating, and two analysts have given it a “hold” rating.

    By Kenneth Smith
  • uploads///ALXN
    Company & Industry Overviews

    Analyzing Alexion Pharmaceuticals’ Product Performance

    Alexion Pharmaceuticals’ (ALXN) key products on the market include Soliris, Strensiq, and Kanuma.

    By Kenneth Smith
  • uploads///capsule _
    Company & Industry Overviews

    How Wall Street Analysts View Merck

    On October 25, Merck (MRK) announced a dividend of $0.55 per share for its outstanding common stock in the fourth quarter of 2018.

    By Daniel Collins
  • uploads///dna _
    Earnings Report

    Allergan Beats EPS and Revenue Estimates: Q3 2018 Earnings

    Allergan (AGN) released its Q3 2018 earnings today. The company beat Wall Street analysts’ estimates for EPS and revenues, and it reported non-GAAP EPS of $4.25 on revenues of $3.91 billion.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Sanofi: Analysts’ Recommendations on October 30

    As of October 30, four analysts are tracking Sanofi. Two analysts recommend a “strong buy,” while two analysts recommend a “hold.”

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Recommendations for Shire as of October 30

    Analysts’ estimates show that Shire (SHPG) stock has a potential to return ~15.8% over the next 12 months.

    By Mike Benson
  • uploads///Oncology
    Company & Industry Overviews

    Johnson & Johnson’s Oncology Business Saw Solid Growth in Q3

    Johnson & Johnson’s (JNJ) oncology business generated revenue of $2.6 billion in the third quarter.

    By Daniel Collins
  • uploads///Chart
    Earnings Report

    Amgen: Analysts’ Recommendations on October 25

    Wall Street analysts expect Amgen’s (AMGN) revenues to decrease marginally by ~0.1% to $5.769 billion during the third quarter.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Amgen: Expect Nearly Flat Revenues in Q3

    New products are expected to deliver double-digit growth, while legacy brands are expected to offset the growth during the quarter.

    By Mike Benson
  • uploads///Immunology
    Company & Industry Overviews

    Stelara and Simponi Drive Johnson & Johnson’s Immunology Business

    Johnson & Johnson’s (JNJ) immunology business generated revenue of $3.4 billion in the third quarter.

    By Daniel Collins
  • uploads///Chart
    Earnings Report

    Allergan’s Q3 2018 Estimates: Revenue Decline Expected

    Analysts are estimating that Allergan’s (AGN) third-quarter revenues will decline 3.8% to $3.88 billion.

    By Mike Benson
  • uploads///dna _
    Earnings Report

    Biogen Surpassed Estimates in Q3 2018, Reports Strong Growth

    Today, Biogen (BIIB) reported EPS of $7.40 on revenues of ~$3.44 billion. BIIB beat the EPS estimate of $6.78 on revenues of ~$3.33 billion.

    By Mike Benson
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.